Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrative Subtype Targeted Therapeutics in ER+, HER2- Breast Cancer
NCT05101564Phase 2Completed
- Sponsor
- Jennifer Lee Caswell-Jin
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib, zotatifin in breast cancer, sponsored by Jennifer Lee Caswell-Jin. Started Mar 2023; status: completed.
02
Drugs
alpelisibzotatifin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05101564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101564.